KRAS G12D-IN-35 

KRAS G12D-IN-35 (example 7) is a potent and orally active KRAS G12D inhibitor. KRAS G12D-IN-35 suppresses p-ERK in AGS cells and potently inhibits the proliferation of various KRAS G12D-mutant cancer cell lines. KRAS G12D-IN-35 inhibits tumor growth in HPAC and GP2D mouse models. KRAS G12D-IN-35 can be used for cancer research, such as pancreatic and colorectal cancer^[1].

1. This compound can be used as a tracer.
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.

703.74

C₃₈H₃₃D₃F₄N₆O₃

C#CC1=C(F)C=CC2=CC(O)=CC(C3=NC4=C5C(N6C[C@H]7CC[C@H](N7)[C@H]6[C@H](C([2H])([2H])[2H])O4)=NC(OCC8(CN9CC/C(CC9)=C(F)\F)CC8)=NC5=C3F)=C21

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shiyi Yang, et al. Crystal form of pyrimidine-containing fused polycyclic derivative inhibitor, and preparation method therefor. WO2025256655A1. 2025-12-18.